Document is current
Any future updates will be listed below
-
Authors
Busschots, Dana http://orcid.org/0000-0003-0887-4119
Bielen, Rob
Koc, Özgür M.
Heyens, Leen
Verrando, Rita
de Galocsy, Chantal
Van Steenkiste, Christophe
Nevens, Frederik
Midgard, Håvard
Dalgard, Olav
Robaeys, Geert
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04251572 at ClinicalTrials.govDocuments that mention this clinical trial
Hepatitis C reinfection in former and active injecting drug users in Belgium
https://doi.org/10.1186/s12954-021-00552-x
-
Funding
Funding for this research was provided by:
gilead sciences (V-2911)
- License Information
-
More Information
Article History
Received: 14 July 2021
Accepted: 27 September 2021
First Online: 12 October 2021
Declarations
:
: The ethical committee approved the study protocol of Ziekenhuis Oost-Limburg on August 23, 2018 (18/0012U). The study protocol is registered at clinicaltrials.gov (NCT04251572). The study was conducted in accordance with the provisions of the Declaration of Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study and all participants provided written informed consent.
: Not applicable.
: DB has received travel grants from AbbVie and Gilead Sciences and research grants from Gilead Sciences; RB has received travel grants from AbbVie, Gilead Sciences and Merck Sharp & Dohme (MSD) and research grants from Gilead and MSD; OK has received a travel grant from Gilead Sciences and research grants from Gilead Sciences and CyTuVax BV; FN has received research grants, consultancy agreements and travel grants in relationship with this manuscript from AbbVie en Gilead; MH has received advisory boards fees and lecture fees from Gilead, AbbVie, and MSD; OD has received research support from AbbVie, Gilead and MSD/MERCK; GR has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and consultancy agreements for AbbVie, BMS, Gilead Sciences and MSD. All other co-authors report no competing interests.
